赛隆药业 (002898)

深圳
11.71
-0.39(-3.22%)
  • :
    15,258,430
  • 卖价/买价:
    11.71/11.72
  • 当日幅度:
    11.52 - 12.15

002898历史数据

时间范围:
每日
2022-11-01 - 2022-12-01
11.7112.0312.1511.5215.26M-3.22%
12.1012.7012.8212.0119.13M-9.23%
13.3314.1514.1512.7427.01M-5.80%
14.1513.5015.1013.2325.20M+0.28%
14.1114.0014.4012.5029.84M+7.79%
13.0911.9913.0911.816.82M+10.00%
11.9012.0912.1411.515.26M-1.57%
12.0912.5012.7811.974.38M-3.36%
12.5112.4912.7412.374.56M-0.95%
12.6312.6712.9212.555.36M-0.08%
12.6412.2912.7912.204.57M+2.85%
12.2912.5512.6512.193.39M-0.89%
12.4012.5812.6212.234.39M-1.35%
12.5711.8512.6411.808.68M+4.75%
12.0012.3212.9311.9211.05M-2.52%
12.3111.9912.5811.706.89M+2.58%
12.0011.8712.2011.685.21M+1.18%
11.8611.6311.9311.355.24M+1.28%
11.7111.1711.9911.177.26M+4.27%
11.2311.1911.4511.156.68M+0.99%
11.1210.7511.2810.657.25M+1.92%
10.9110.6311.1010.418.87M+2.54%
10.6410.5510.7710.238.17M+1.43%
最高: 15.10最低: 10.23差价: 4.87平均: 12.23涨跌幅: 11.63
  • 赛隆药业最新股东户数1.44万户,呈现连续10期下降,股东户数低于市场平均水平。公司户均持有流通股份4573股;户均流通市值5.88万元,低于市场平均水平。, 因公司销售受国家重点监控药品目录政策的影响,为稳定市场份额,对信用良好的客户采取授信政策,应收账款额度同比增长较大,从而导致经营活动产生的现金流量净额与净利润出现差异。了解了赛隆药业公司与研发支出资本化相关的内部控制,评价其设计的合理性。, 因公司销售受国家重点监控药品目录政策的影响,为稳定市场份额,对信用良好的客户采取授信政策,应收账款额度同比增长较大,从而导致经营活动产生的现金流量净额与净利润出现差异。了解了赛隆药业公司与研发支出资本化相关的内部控制,评价其设计的合理性。 资料来源:资产信息网(小程序:资产信息)
    0